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Abstract 
Introduction: Ischaemic stroke (IS) is a disease that is a common cause of death and one of the most common causes of disability in adults. 
There is a continuous need to conduct stroke pathogenesis studies. A certain role here can be attributed to adipose-derived hormones. 
The aim of this paper is to assess the blood concentration for selected adipocytokines: omentin-1, irisin, protein-1 related with C1q/TNF 
(CTRP1), vaspin and nesfatin-1 in IS patients, and an attempt to define their role as risk factors for ischaemic stroke.
Material and methods: The study included 46 patients with ischaemic stroke (27 females, 19 males, average 67.6 years of age). The control 
group consisted of 32 patients (16 females, 16 males, average 64.1 years of age) who had never had cerebrovascular diseases.
Results: The concentration of omentin-1 and CTRP1 in the group of stroke patients was higher than in the control group, whereas the 
concentrations of nesfatin-1 and irisin was significantly lower than in the control group. The vaspin level was similar in both groups 
of patients. Statistical analysis using logistic regression allows us to find that CTRP1 can be a significant stroke risk factor. A statistically 
significant positive correlation was found between the concentration of CTRP1 and NIHSS. However, no correlation between the con-
centration of other adipocytokines under investigation and the severity of ischaemic stroke was found.
Conclusions: From among the adipocytokines under investigation, higher concentrations of omentin-1 and CTRP1 and lower blood 
concentrations of nesfatin-1, irisin significantly increase the odds of getting to the group of ischaemic patients. It seems that CTRP1 can 
be an independent predictive factor of IS. (Endokrynol Pol 2020; 71 (6): 504–511)
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Introduction
Ischaemic strokes (IS) make up about 80% of all 
strokes. An insufficient blood flow through cerebral 
vessels results in cerebral hypoxia, impaired glucose 
supply, and impaired removal of unnecessary metabo-
lites, which results in a cerebral infarction. Despite the 
progress in diagnostic and therapeutic methods, IS 
remains one of the most common causes of long-term 
disability in adults, being also a significant cause of 
death. It turns out that both primary and secondary 
prevention are still very important in health care cover-
ing patients with cerebrovascular diseases. Hence, it is 
extremely important to gain detailed knowledge of the 
pathology and pathogenesis of stroke [1].
In recent years it has been proven that adipose tis-
sue not only plays the role of basic energy storage and 
provides body thermal insulation, but it is also an en-
docrine organ producing many mediators — so-called 
adipocytokines. It seems that adipose tissue plays a role 
in regulating many life processes, including appetite, 
and maintaining metabolic homeostasis. It is the site 
where steroid and thyroid hormones are metabolised. 
White adipose tissue participates in many hormonal 
and inflammatory processes. It affects metabolism by 
playing a role in shaping energy homeostasis, resistance 
to insulin, and adipocyte differentiation. The visceral 
adipose tissue is responsible for local and generalised 
inflammations and insulin resistance, which is pro-
vided by generating and secreting numerous proteins 
and cytokines, including adiponectin, resistin, leptin, 
omentin or tumour necrosis factor alpha (TNF-a), 
interleukin 6 (IL-6), and monocyte chemoattractant 
protein-1 (MCP-1) [2, 3].
Studies on the influence of adipose tissue on the 
atherosclerosis, especially in terms of inflammatory 
mechanisms, have been conducted for years. The role 
of adipocytokines in developing diseases, including 
diabetes, hypertension, thyroid disorders, peripheral 
vascular diseases, or Alzheimer disease is investigated. 
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The control group included 32 patients (16 females, 16 males, aver-
age 64.1 years of age) without cerebrovascular diseases in history, 
who had not suffered any chronic diseases except for back pain 
syndrome and arterial hypertension.
The patients underwent routine laboratory tests [complete blood 
count (CBC), total cholesterol, low-density lipoprotein (LDL), 
high-density lipoprotein (HDL), triglycerides (TG), electrolyte 
level: sodium (Na), potassium (K), magnesium (Mg), chloride (Cl), 
thyroid-stimulating hormone (TSH), free  triiodothyronine (fT3), 
free thyroxine (fT4), C-reactive protein (CRP), creatinine, fasting 
glycaemia, and international normalised ratio (INR)]. Their body 
mass index (BMI) was also calculated. Ischaemic stroke patients 
were subject to stroke severity evaluation by using the Barthel scale 
on day 1 and 9 after stroke and the National Institutes of Health 
Stroke Scale (NIHSS scale), and they underwent blood flow tests in 
extra and intracranial arteries by using Doppler ultrasound method 
to assess the occurrence of stenosis and to assess the intima media 
thickness (IMT).
An additional full blood sample (20 mL) was collected from each 
patient. The blood was centrifuged, and the serum obtained was 
frozen at –80°C. Once all the materials were ready, the levels of 
omentin-1, irisin, CTRP1, vaspin were determined by using com-
mercially available immunoenzymatic test kits from BioVendor, 
while the concentration of nesfatin-1 was measured by using a test 
kit manufactured by Cloud-Clone Crop.
The database was created in Microsoft EXCEL v. 2010, and statistical 
calculations were conducted by using licensed statistical packages: 
Statistica v. 7.1 PL supplied by StatSoft, MedCalc Statistical Software 
v.14.10.2 and PQStat Software v. 1.6.6. During the statistical analysis 
a significance level of p < 0.05 was assumed. The distribution of 
variables was determined by using the Shapiro-Wilk test. In addi-
tion, the following statistical tests were used: parametric Student’s 
t-test, Fisher’s exact test for two variances, Mann-Whitney U test, 
chi-square test of independence, Pearson’s correlation coefficient 
test, nonparametric Spearman’s rank correlation coefficient test, 
and simple and multifactorial logistic regression. 
In the past we published a paper that covered different cytokine 
sets. In the previous study we tested the levels of resistin, chemerin, 
and visfatin. The same patient base was used for the studies. That 
is why the study group and control group are identical for both 
studies. Because the same population of patients was investigated, 
some of the data can be the same, e.g. general characteristics of the 
study and control group, presented in Table 1 [15].
The Bioethics Committee operating at the Regional Medical Cham-
ber in Łódź (K.B. No. -7/17 of 5 April 2017) granted permission to 
conduct the study.
Results
No statistically significant differences were noticed 
between the study and control group in terms of basic 
biochemical parameters and BMI, while with the group 
with IS the percentage of patients with elevated fast-
ing glycaemia and elevated CRP as well as with lower 
potassium concentration was higher (Tab. 1).
The concentration of omentin-1 in the study group 
ranged from 196 to 1159.7 ng/mL, with an average value 
of 487.1 ± 201.22 ng/mL, while in the control group 
it ranged from 183.2 to 561.1 ng/mL, with an average 
value of 362.4 ± 106.29 ng/mL. In the study group the 
concentration of omentin-1 was statistically significantly 
higher than in the control group (p = 0.0084) (Tab. 2). 
The concentration of irisin in the study group 
ranged from 3.09 to 8.69 ng/mL, with an average value 
Obesity, because of its coincidence with developing 
cardiovascular diseases, is perceived as an increasingly 
significant clinical problem. The role of adipose tissue 
and the mechanisms of action of proteins secreted by 
adipose tissue in the context of IS have not been fully 
explored [4–6].
Omentin-1 is a protein produced mainly by the 
visceral adipose tissue, which probably increases 
the susceptibility of adipose tissue to insulin. It also 
shows some anti-inflammatory action by reducing 
the expression of C-reactive protein, tumour necrosis 
factor, and nuclear transcription factor. It is believed 
that a reduced omentin level can develop an insulin 
resistance. Currently, it is known that in patients with 
type 2 diabetes and in obese people, the omentin level 
is decreased [7, 8].
Irisin is an adipomyokine that is released both in 
skeletal muscles and in white adipose tissue. Study 
results show a correlation between the irisin concen-
tration and disorders of carbohydrate metabolism. It 
seems that it exerts a beneficial influence by maintain-
ing correct carbohydrate metabolism parameters, and 
it helps improve the insulin sensitivity of tissues. It is 
also referred to as an antidiabetic hormone [9].
Vaspin sensitises peripheral tissues to insulin and 
shows a hypoglicemising effect [10, 7]. It can protect 
the vascular endothelial cells against apoptosis induced 
by free fatty acids, which suggests its beneficial antiath-
erosclerotic effect [11].
Nesfatin-1 is an appetite-suppressing neuropeptide 
generated in the mammalian hypothalamus. Like other 
appetite stimulating (e.g. ghrelin) or appetite suppress-
ing hormones (e.g. leptin), it also shows some gastropro-
tective properties — it protects gastric mucosa against 
damage induced by corrosive factors and stress-induced 
microbleeds [12, 13].
Tumour necrosis factor-a-related protein 1 (CTRP1) 
is a new adipokine that belongs to the CRTP family and 
occurs in many tissues. It acts as a key regulator for the 
metabolism of glucose and lipids. Currently there are 
16 members of the CRTP family identified, and they 
share a common structure [14].
Material and methods
The study group included 46 patients with IS (27 females, 19 males, 
average 67.6 years of age). The trial inclusion criterion is confirmed 
IS defined as a clinical syndrome featuring a sudden focal, some-
times generalised brain function disorder with symptoms persisting 
longer than 24 hours. Blood for tests was collected within 24 hours 
of detecting the first symptoms and before implementing treatment. 
Trial exclusion criteria include the following: haemorrhagic stroke, 
subarachnoid haemorrhage, brain tumour or any type of cancer, 
kidney/liver failure, severe infection, injury, surgery, myocardial 
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of 4.86 ± 1.31 ng/mL, while in the control group it 
ranged from 1.57 to 9.1 ng/mL with an average value 
of ± 6.07 ng/mL. In the group of IS patients the con-
centration of irisin was statistically significantly lower 
than in the control group (p < 0.0001) (Tab. 2).
The concentration of vaspin in the study group 
ranged from 0.031 to 0.655 ng/mL, with an average 
value of 0.217 ± 0.161 ng/mL, while in the control group 
it ranged from 0.057 to 0.688 ng/mL, with an average 
value of 0.23 ± 0.874 ng/mL. A comparison of the 
concentration of vaspin in both groups did not reveal 
any statistically significant differences (p < = 0.5646) 
(Tab. 2).
The concentration of nesfatin-1 in the study group 
ranged from 58 to 850.6 ng/mL, with an average value 
of 295.8 ± 175.7 ng/mL, while in the control group it 
ranged from 126.9 to 864.5 ng/mL, with an average 
value of 387.5 ± 0.874 ng/mL. In the study group the 
concentration of nesfatin-1 was significantly lower than 
in the control group (p = 0.0282) (Tab. 2).
The level of CTRP1 in the study group ranged 
from 200 to 949.5 ng/mL, with an average value of 
447.8 ± 1.31 ng/mL, while in the control group it 
ranged from 205 to 689, ng/mL, with an average 
value of 335.4 ± 104.1. In the group of IS patients 
the concentration of that adipocytokine was statisti-
cally significantly higher than in the control group 
(p < 0.0002) (Tab. 2).
Logistic regression allowed us to assess that CTRP 1 
was a significant risk factor for stroke (Tab. 3).
A statistically significant correlation between the 
concentration of omentin-1, CTRP1, nesfatin-1, and 
the age of patients in the study group was found. 
The concentration of omentin-1 and CRTP1 increased 
Table 1. Characteristics of patients with ischaemic stroke (IS) and control group
Ischaemic stroke (n = 46) Control (n = 32) p value
Age (years) 67.6 (SD ± 12.92) 64.1 (SD ± 64.1) 0.0851
Total cholesterol [mg/dL] 186 (SD ± 55.52) 195.6 (SD ± 35.77) 0.2161
HDL [mg/dL] 50.7 (SD ± 14.12) 57.8 (SD ± 11.28) 0.0093
LDL [mg/dL] 118.7 (SD ± 39.4) 130.6 (SD ± 34.48) 0.1892
TG [mg/dL] 148.1(SD ± 78.81) 118.7 (SD ± 63.51) 0.1042
Na [mmol/L] 139.3 (SD ± 3.13) 139.6 (SD ± 2.55) 0.6772
K [mmol/L] 3.93 (SD ± 0.45) 4.22 (SD ± 0.47) 0.0078
Mg [mg/dL] 1.98 (SD ± 0.25) 2.02 (SD ± 0.2) 0.1793
Cl [mmol/L] 102.7 (SD ± 4.25) 103 (SD ± 3.2=19) 0.5681
Creatine [mg/dL] 0.88 (SD ± 0.28) 0.76 (SD ± 0.19) 0.5681
TSH [uIU/mL] 1.72 (SD ± 1.69) 1.29 (SD ± 0.94) 0.4951
fT3 [pg/dL] 2.68 (SD ± 0.59) 2.71 (SD ±  0.54) 0.7862
fT4 [ng/dL] 1.45 (SD ± 0.4) 1.29 (SD ± 0.21) 0.1425
Thrombocytes [K/uL] 231 (SD ± 73) 234.5 (SD ± 52.3) 0.4887
Leukocytes [K/uL] 8.63 (SD ± 2.43) 8.05 (SD ± 2.55) 0.2223
CRP [mg/dL] 0.57 (SD ± 0.73) 0.33 (SD ± 0.53) 0.0367
Fasting glycaemia [mg/dL] 107.7 (SD ± 32.4) 93.8 (SD ± 10.7) 0.0477
BMI 27.3 (SD ± 4.5) 27.4 (SD ± 4.1) 0.9615
HDL — high-density lipoprotein; LDL — low-density lipoprotein; TG — triglycerides; Na — sodium; K — potassium; Mg — magnesium; Cl — chlorine; TSH — thyroid 
stimulating hormone; fT3 — triiodothyronine; fT4 — thyroxine; CRP — C-reactive protein; BMI — body mass index
Table 2. Omentin-1, vaspin, irisin, nesfatin-1, and CTRP1 in patients with ischaemic stroke (IS) and in the control group
Ischaemic stroke (n = 46) Control (n = 32) p value
Omentin-1 [ng/mL] 487.1 362.4 p = 0.0084
Irisin [ng/mL] 4.86 6.13 p < 0.0001
Vaspin [ng/mL] 0.217 0.23 p = 0.5646
Nesfatin-1 [ng/mL] 295.8 387.5 p = 0.0282
CTRP1 [ng/mL] 447.8 335.4 p = 0.0002
CTRP1 — protein-1 related with C1q/TNF
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with the age of patients in the study group, while 
the concentration of nesfatin-1 decreased. This cor-
relation was not observed for the remaining adipo-
cytokines (Tab. 4).
No differences in adipocytokine blood concentra-
tions between male and females were found (Tab. 5).
A statistically significant positive correlation was 
found between the concentration of CTRP1 and the 
NIHSS. However, such a correlation was not observed 
for vaspin, omentin-1, nesfatin-1, and irisin. No correla-
tion between the concentrations of the adipocytokines 
under analysis and the Barthel scale score on day 1 and 
day 9 in IS patients was found (Tab. 6).
No correlation between the concentrations of adipo-
cytokines under analysis and the IMT was found (Tab. 7).
For the concentrations of omentin-1, irisin, vaspin, 
and CTRP1 no differences between patients with and 
without the stenosis of carotid arteries were found. 
We noted a higher concentration of nesfatin-1 only in 
patients with stenosis (Tab. 8).
Table 6. Correlations of blood adipocytokines concentrations with NIHSS, Barthel scale in patients with cerebral stroke
NIHSS scale Barthel start Barthel end
Omentin-1 [ng/mL]
R 0.2384 –0.1915 –0.2926
P value 0.1678 0.2703 0.0881
Irisin [ng/mL]
R 0.0200 0.0154 –0.0446
P value 0.8952 0.9195 0.7685
Vaspin [ng/mL]
R –0.1883 0.1608 0.1077
P value 0.2101 0.2857 0.4761
Nesfatin-1 [ng/mL]
R –0.0737 0.0507 –0.0702
P value 0.6304 0.7409 0.6488
CTRP1 [ng/mL]
R 0.3569 –0.3099 –0.2459
P value 0.0149 0.0571 0.0995
CTRP1 — protein-1 related with C1q/TNF; NIHHS scale — scale of National Institutes of Health Stroke Scale; Barthel start — Barthel scale evaluation on admission; 
Barthel end — Barthel scale evaluation on ninth day after admission
Table 3. Multifactorial logistic regression for CTRP1
Multifactorial logistic regression (p < 0.0001; R2Nagelkere = 0.2937)
Coefficient St. error p Odds ratio 95% CI
CTRP1 0.0078 0.0023 0.0201 1.0078 1.0012-1.0145
Fixed –5.8865 4.0670 0.1478
CTRP1 — protein-1 related with C1q/TNF; CI — confidence interval
Table 4. The correlation between omentin-1, vaspin, irisin, 
nesfatin-1, CTRP1, and the age of ischaemic stroke patients
R p value
Omentin-1 and age 0.3865 0.0218
Irisin and age 0.1518 0.3138
Vaspin and age –0.0601 0.6914
Nesfatin-1 and age –0.3039 0.0424
CTRP1 and age 0.5173 0.0002
CTRP1 — protein-1 related with C1q/TNF
Table 5. Evaluation of average concentrations for omentin-1, vaspin, irisin, nesfatin-1, and CTRP1 in females and males with 
ischaemic stroke
Females (n = 27) Males (n = 19) p value
Omentin-1 [ng/mL] 516.6 452.1 p = 0.6121
Irisin [ng/mL] 4.97 4.7 p = 0.9648
Vaspin [ng/mL] 0.244 0.180 p = 0.2976
Nesfatin-1 [ng/mL] 280.2 319.3 p = 0.3639
CTRP1 [ng/mL] 484.4 395.7 p = 0.0818
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Discussion
The literature shows numerous publications that attri-
bute the role of developing IS to adiponectin, resistin, 
or leptin [15, 16]. There are only limited reports describ-
ing the pathogenic role in developing stroke of other, 
less renowned adipocytokines, including omentin-1, 
CTRP1, nesfatin-1, irisin, and vaspin. Proving the cor-
relation between the existence of cerebrovascular events 
and the concentration of adipose-derived hormones in 
the blood of IS patients can extend the knowledge of 
the pathogenesis of IS.
Omentin-1
The literature contains analyses of the omentin-1 
level in the context of atherosclerosis. Shang et al. [17] 
proved that the serum concentration of omentin-1 
can be a sensitive biomarker for the development and 
progression of atherosclerotic lesions in the coronary 
vessels of persons with metabolic syndrome. Other 
study results show their correlation with the level of 
atherosclerotic lesions. A negative correlation between 
the blood serum concentration of omentin-1 and the 
clinical exponents for atherosclerosis severity in pa-
tients with type 2 diabetes and a metabolic syndrome 
was found [18]. Multiple regression analysis conducted 
by Yool H. et al. [19] showed that the concentration of 
omentin-1 was an independent determining factor for 
atherosclerosis severity in patients with type 2 diabetes.
It was also found that the serum concentration of 
omentin-1 was lower in persons with acute coronary 
syndrome and with stable angina pectoris than in per-
sons without those disorders. In addition, the persons 
with acute coronary syndrome showed lower omen-
tin-1 concentration than patients with stable angina 
pectoris [20].
In recent years there have been reports concerning 
the role of omentin-1 in IS. Wu et al. [21] attempted to 
assess the impact of serum omentin-1 concentration on 
the prognosis of IS patients, without diabetes in their 
medical history. It was found that a low omentin-1 con-
centration increased the risk of treatment failure. On 
the other hand, Xu et al. [22] in their study found that 
omentin-1 could be a biomarker used to predict the in-
stability of an atherosclerotic plaque in patients with IS. 
Patients with IS and an unstable atherosclerotic plaque 
had a considerably higher level of the adipocytokine 
than patients with a stable atherosclerotic plaque. In 
our study, to our surprise, we found a higher omen-
tin-1 concentration in the group of stroke patients. We 
found no correlation between the omentin-1 level and 
the stroke severity, IMT, or the occurrence of stenosis 
in carotid vessels.
Irisin
Irisin has been analysed several times in the context of 
physical effort. It is suggested that its secretion increases 
with an intensification of physical effort, especially 
after high-intensity resistance training [23]. The results 
of studies performed to date are divergent [24]. For 
example, Norheim et al. [25] reported a 2-fold increase 
in the irisin level directly after high-intensity physical 
effort, but its concentration reduced in response to 
a 12-week mixed strength-endurance training.
Irisin has become the focus of attention as a potential 
new marker not only for obesity, but also for obesity-re-
lated metabolic disorders [26]. A negative correlation 
between serum irisin levels and the incidence rate of 
coronary disease was described [27]. A lower irisin 
level was not only an independent predictive factor for 
complications in major vessels in type 2 diabetes [26], 
Table 7. Correlations of blood adipocytokines concentrations 
with intima-media (IM) complex
Intima-media complex
R p value
Omentin-1 [ng/mL] –0.1068 0.5743
Irisin [ng/mL] 0.2635 0.0959
Vaspin [ng/mL] –0.1074 0.2101
Nesfatin-1 [ng/mL] 0.1311 0.4201
CTRP1 [ng/mL] –0.0358 0.8243
CTRP1 — protein-1 related with C1q/TNF
Table 8. Omentin-1, irisin, vaspin, irisin, nesfatin-1, and CTRP1 levels in patients with ischaemic stroke with and without 
carotid artery stenosis detected in carotid Doppler ultrasonography
Patients without stenosis (n = 36) Patients with stenosis (n = 5) p value
Omentin-1 [ng/mL] 513 (SD ± 216.24) 387.93 SD ± 39.38) 0.3498
Irisin [ng/mL] 4.71 (SD ± 1.36) 5.55 (SD ± 1.79) 0.2827
Vaspin [ng/mL] 0.206 (SD ± 0.152) 0.303 (SD ± 0.214) 0.3397
Nesfatin-1 [ng/mL] 271.3 (SD ± 165.4) 436.5 (SD ± 76.5) 0.0213
CTRP1 [ng/mL] 467.2 (SD ± 176.1) 347.5 (SD ± 130.9) 0.0994
CTRP1 — protein-1 related with C1q/TNF
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but also for cardiovascular events, including MI in the 
population of non-diabetic patients [29].
In the literature there are only a small number of 
reports from the last 4 years on the role of irisin in IS. 
Li et al. [30] found that the concentration of serum irisin 
in mice fell after IS. Moreover, the irisin level was nega-
tively correlated with the cerebral infarction volume, 
advanced neurological deficit, and with the concentra-
tion of TNF-a and IL-6. Administering recombined irisin 
to mice with IS reduced the volume of cerebral infarc-
tion and neurological deficits. Another experimental 
study on mice, inducing their global cerebral ischaemia, 
confirmed that irisin improved neurologic functions, 
and additionally it was found to reduce apoptosis and 
alleviate damage to neurons [31]. A study covering 
a Chinese population including more than 1500 persons 
with IS, subjected to a 6-month neurological observa-
tion, showed that irisin level reduction is associated 
with worse prognosis [32]. However, our analysis did 
not show any correlation between irisin level and the 
severity of stroke, but we confirmed that the patients 
with IS showed higher concentrations of irisin than 
healthy persons.
Vaspin
In obese patients with a normal glucose tolerance, 
the level of vaspin was usually elevated. Its secretion 
increases with the volume of adipose tissue and BMI 
[33]. In addition, it was shown that the serum concen-
tration of vaspin was higher in females than in males 
with normal glucose tolerance, but we did not note 
such differences [34]. It is suggested that the increase 
in vaspin expression can be a compensation mechanism 
as a response to the increase in obesity and insulin 
resistance [35]. The concentration of vaspin can also 
reflect the level of glycaemic control. In patients with 
type 2 diabetes a positive correlation between the serum 
concentration of vaspin and the HbA1c value was ob-
served [36]. Some authors suggest that vaspin protects 
vascular endothelial cells against apoptosis induced by 
free fatty acids, which indicates that it can show an an-
tiatherosclerotic effect [11]. Li et al. [37] showed that 
a low vaspin concentration correlated with the severity 
of ischaemic heart disease and unstable angina pectoris.
Only a few studies assessing the concentration of 
vaspin after IS have been performed so far, and the 
published results are very divergent. Aust et al. [38] 
found lower vaspin concentrations in patients with 
carotid artery stenosis and cerebral ischaemic event in 
their history. At the same time, the study did not show 
any correlation between vaspin serum concentration 
and the severity of atherosclerotic lesions. However, 
they found a positive correlation between the serum 
concentration of vaspin and leptin, another adipocyto-
kine related to the development of atherosclerosis. An-
other study showed a lower vaspin level in patients 
with acute IS [39]. However, we did not confirm such 
a correlation. The group of patients with and without 
stroke was homogeneous in terms of the adipocyto-
kine concentration. Some authors, conversely, noted 
higher levels of the adipocytokine in patients with IS 
[40]. It should be emphasised that despite the fact that 
the above-mentioned studies (including ours) refer to 
acute-phase IS, they cover only small groups of patients, 
and we do not possess any meta-analytic data.
Nesfatin-1
As already mentioned above, nesfatin-1 is a peptide 
with an anorexigenic and gastroprotective effect [13, 14]. 
In addition, it has been found that nesfatin-1 affects the 
cardiovascular system. By stimulating the action of the 
sympathetic nervous system, it increases the average 
arterial blood pressure [41]. Lower levels of nesfatin-1 
were observed in patients with acute MI [42] and in 
patients with impaired flow through coronary vessels 
[43]. Ding et al. [44] found a correlation between low-
ered nesfatin-1 serum levels and the development and 
intensification of peripheral vessel diseases in diabetic 
patients. The above-mentioned nesfatin-1 related stud-
ies may suggest that it plays a role in atherosclerosis, 
and consequently in the mechanism of developing IS. 
Kuyumcu [45] investigated the correlation between nes-
fatin-1 level and the atherosclerosis of carotid arteries 
and found that the serum levels of nesfatin-1 in patients 
with carotid artery stenosis were lower, especially if the 
stenosis exceeded 60%. In addition, the concentration 
of the adipocytokine was negatively correlated with 
the speed of carotid artery narrowing. The low level 
of nesfatin-1 proved to be an independent risk factor 
for carotid artery stenosis. Observations showed that 
its lower concentrations were concomitant with an un-
stable atherosclerotic plaque.
Our study showed lower nesfatin-1 concentrations 
in patients with IS with no correlation with stroke se-
verity. Interestingly, patients with stenosis had higher 
nesfatin-1 concentrations than patients without it. How-
ever, it should be noted that the group consisted only of 
five patients. A study performed by Erfani S et al. [46] 
for the first time showed that administering nesfatin-1 
to rats with induced cerebral ischaemia prevents the 
death of neurons.
CTRP1
CTRP1 acts as a blood pressure regulator [47]. Patients 
with arterial hypertension have higher CTRP1 levels 
as compared to normotensive persons. Tang et al. [48] 
showed that an increase in CTRP1 and IL-6 levels 
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disease. Also, Lu et al. [49] documented that CTRP1 
was elevated in patients with stable coronary disease, 
and by using a multidimensional analysis they con-
cluded that CTRP1 was an independent risk factor for 
its occurrence. CTRP1 levels grow with the increase 
of CAD severity. In addition, they are positively cor-
related with the increase of TNF and IL-6 levels. Also, 
the correlation of CTRP1 with a future cardiovascular 
risk was investigated. In patients undergoing coronary 
angiography they measured the level of CTRP1 and 
then observed them for 8 years for future cardiovascu-
lar events (including deaths caused by cardiovascular 
incidents, the occurrence of myocardial infarction, and 
stroke). Obesity, metabolic syndrome, type 2 diabetes, 
and fatty liver disease (FLD) were associated with 
a higher CTRP1 level. High CTRP1 serum levels were 
significantly related to the risk of future cardiovascular 
events (including stroke) [50].
Despite such a large number of unambiguous 
reports on elevated CTRP1 levels in coronary artery 
disease, we do not possess any studies concerning the 
level of that adipocytokine in IS. Our analysis showed 
not only significantly higher CTRP1 concentrations in 
patients with IS, but also defined CTRP1 to be an in-
dependent predictive factor for IS. Moreover, higher 
CTRP1 concentrations were associated with more 
severe course of stroke.
Summing up, the lower levels of nesfatin-1 and irisin 
in the blood of patients with IS observed in our study 
are convergent with the studies conducted by other 
authors, which allows us to assume that there might be 
pathogenetic connection between these levels and IS.
The results of our study show that CTRP1 can be 
a useful diagnostic marker for IS, as is the case for 
ischaemic heart disease.
Conclusions
An early detection of risk factors for vascular diseases 
and implementing primary prevention leads not only 
to the reduction in morbidity and mortality caused by 
stroke, but also improves patients’ quality of life and 
reduces the costs of treating the consequences of those 
diseases. The role of adipocytokines in the pathogen-
esis of IS, repeatedly emphasised in the literature, and 
confirmed by us, urges us to investigate more and more 
new adipose-derived hormones. Clinicians hope to find 
sensitive markers for vascular diseases, including cere-
brovascular diseases, which could be used to identify 
patients endangered by the diseases.
Although, our analysis has shown that CTRP1 
turned out to be an independent risk factor for stroke, it 
is almost impossible for us to compare our study results 
to the results obtained in studies performed by other 
authors. It seems that there is an urgent need to con-
tinue this new line of studies on the pathogenesis of IS.
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